CIT expands US presence

Appoints vice-president of business development North America

CIT, a French non-clinical CRO, has opened a US subsidiary, CITox, in Boston, Massachusetts, to spearhead the planned expansion of its US activities.

The company has appointed Bernard Galat as vice-president, business development, North America, who will be based in the Boston office.

The US represents 15% of CIT’s current sales; the aim is to increase this to 30% in three to five years.

Prior to joining CIT, Galat held senior sales and marketing positions with Xceleron, Parexel and Carestat.

‘This is an exciting time to be joining CIT as we expand the availability of our services in monoclonal antibody therapies, tissue cross-reactivity, functional genomics, safety pharmacology and carcinogenicity, including transgenic models,’ he said.

You may also like

Research & Development

CiToxLAB expands inhalation test capabilities in North America and Europe

Opens rodent and non-rodent facility in Canada and will double rodent capacity in Hungary
Regulatory

CiToxLAB emerges from CIT and LAB Research merger

Will provide pre-clinical and specialist services from four facilities
Regulatory

CIT acquires assets of LAB Research Inc

This acquisition makes the new group one of the world’s top preclinical CROs
Research & Development

CIT to purchase LAB Research

Acquisition will take Canadian CRO out of receivership
Regulatory
Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS

Pheno Therapeutics gains FDA IND clearance for first-in-class GPR17 antagonist PTD802 in MS

The clearance enables a first-in-human trial of the UCB-licensed remyelination candidate, marking the first GPR17 programme to reach clinical development for multiple sclerosis and related demyelinating diseases
Research & Development
Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker

Promega UK Launches Lumit Cell Proliferation Assay (Human Ki-67) for rapid, wash-free detection of a key proliferation marker

New homogeneous, plate-based assay enables researchers to track hKi-67 in a simple add-and-read format, delivering robust and reproducible results in less time
Research & Development
BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset

BioArctic and Lilly sign $30m collaboration combining BrainTransporter with Lilly neurodegeneration asset

The deal, worth up to $800m including milestones, marks BioArctic's fourth BrainTransporter partnership — joining existing collaborations with Eisai, Bristol Myers Squibb and Novartis to advance brain-targeted biologics delivery
Subscribe now